Prescribing pattern of anticancer drugs in the medical oncology department of a tertiary care teaching hospital

Abstract

Background: To study drug utilization of anticancer drugs in the oncology inpatient department (IPD) of Kamineni Hospitals, L.B. Nagar, Hyderabad, India.Methods: One hundred prescription records were screened and analysed as per the study parameters from the oncology IPD of Kamineni Hospitals, Hyderabad. Commonly used anticancer drugs were recorded; furthermore, different types of carcinomas were noted.Results: Age group of patients was in between 04 and 80 years, 62 were females and 38 were male patients. The most common type of carcinoma was carcinoma of the breast (28%). Cisplatin was the most commonly used anticancer drug (29%). Adjuvant drugs were used in 98% of the patients.Conclusions: Incidence of cancer is more in females than males. Adjuvant and cytoprotective drugs used may have had a bearing on the relatively lower incidence of adverse effects.

Assessment of Prescription Pattern of Chemotherapy in Subjects with Esophageal Cancer

“…Anticancer drugs were administered either singly or in combination. In our study, the majority of patients received dual therapy (75%) followed by and 11% triple therapy, 4% monotherapy, but this result differs from the study by Ravindra S. Beedimani et al, in which the author found that the majority (63%) of patients received monotherapy while 37% received a combination of anticancer drugs [15]. On analysing the prescription, the majority of SCC subjects received a carboplatin based dual drug therapy (combination of carboplatin and irinotecan or docetaxel or paclitaxel) followed by triple drug therapy (combination of docetaxel, 5-fluorouracil, and oxaliplatin or carboplatin, paclitaxel and trastuzumab) and the majority of AC subjects received a FLOT therapy followed by paclitaxel based dual therapy (combination of paclitaxel + cetuximab or ramucirumab or trastuzumab) and CAPOX also, NEC subjects received carboplatin and irinotecan combination.…”

“…On analysing the prescription, the majority of SCC subjects received a carboplatin based dual drug therapy (combination of carboplatin and irinotecan or docetaxel or paclitaxel) followed by triple drug therapy (combination of docetaxel, 5-fluorouracil, and oxaliplatin or carboplatin, paclitaxel and trastuzumab) and the majority of AC subjects received a FLOT therapy followed by paclitaxel based dual therapy (combination of paclitaxel + cetuximab or ramucirumab or trastuzumab) and CAPOX also, NEC subjects received carboplatin and irinotecan combination. The result of this study differs from the study by Mary Rohini Pentareddy et al, in which the author found that the majority of the patients received Paclitaxel and carboplatin, Oxaliplatin and 5-FU [15]. Our study also observed that the most commonly received supportive therapies were ondansetron and pheniramine maleate for all subjects, followed by pantoprazole and 0.9% sodium chloride (96%), dexamethasone (93%), hydrocortisone succinate (50%), ranitidine (21%), leucovorin (14%), and filgrastim (11%).…”

“…Out of the 28 subjects included in the study, the majority were in the age range of 51-80 years. The age wise distribution of the subjects showed that the prevalence of esophageal cancer was higher in the age group of 61-70 years, which is similar to the age group of participants in the study of Mary Rohini Pentareddy et al, in which it was observed that age-related events are responsible for the higher prevalence of cancer in the elderly [10].…”

Assessment of anticancer drug utilization pattern and patients’ survival—A single center experience from Saudi Arabia

“…This pattern occurred due to the variety of cancers that affect patients in our geographical area, which is also consistent with the prevalence of cancers treated with these protocols. [16][17][18] Doxorubicin, cyclophosphamide, and docetaxel accounted for the most commonly involved chemotherapeutic agents in our study, which is related to the prevalence of gastrointestinal and breast cancers that were predominant in our cohorts in SA. 13,18 Different chemotherapeutic agents may be used variably depending on the cancer institute's focus or specialization, or the incidence of cancer in the involved region.…”